Frazier Life Sciences Management’s Jade Biosciences JBIO Stock Holding History

Frazier Life Sciences Management’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,413,280	Closed	-$12.2M	–	44
2025 Q3	$12.2M	Sell	1,413,280 -358,836	-20%	-$2.93M	0.37%	37
2025 Q2	$17.7M	Buy	+1,772,116	New	+$60.3M	0.71%	31
2024 Q2	–	Sell	-34,425	Closed	-$35.6M	–	51
2024 Q1	$35.6M	Hold	34,425	–	–	1.5%	21
2023 Q4	$27.3M	Hold	34,425	–	–	1.46%	20
2023 Q3	$16.4M	Buy	34,425 +6,000	+21%	+$3.25M	1.09%	21
2023 Q2	$17.1M	Buy	28,425 +18,765	+194%	+$12M	1.02%	25
2023 Q1	$6.82M	Buy	+9,660	New	+$8.01M	0.49%	38

Other funds holding JBIO

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return